Drug Development's Preclinical Bottleneck
This article was originally published in Start Up
Executive Summary
Thanks to genomics, combinatorial chemistry, and high-throughput screening, pharmaceutical companies have more drug leads than ever. But which are the drugs? Start-up firms with faster, smarter approaches to preclinical testing may help sort out the answers. Information technology will play a key role in lead optimization as new firms with simulation software are helping drug developers plot development strategies earlier than ever.